Comparative Pharmacology
Head-to-head clinical analysis: PROMETHAZINE PLAIN versus ZYRTEC ALLERGY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROMETHAZINE PLAIN versus ZYRTEC ALLERGY.
PROMETHAZINE PLAIN vs ZYRTEC ALLERGY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Promethazine is a phenothiazine derivative that acts primarily as a histamine H1 receptor antagonist, blocking the effects of histamine at H1 receptors. It also has anticholinergic, antiemetic, sedative, and local anesthetic properties. Its antiemetic effect is mediated through blockade of dopamine D2 receptors in the chemoreceptor trigger zone.
Selective peripheral histamine H1-receptor antagonist; inhibits histamine release from mast cells and basophils.
25-50 mg orally, intramuscularly, or rectally every 4-6 hours as needed; maximum 100 mg per dose
5–10 mg orally once daily; maximum dose 10 mg/day.
None Documented
None Documented
Terminal elimination half-life: 10-19 hours (average 12-15 hours). Clinical context: Requires repeated dosing for sustained effect; dosing interval typically every 6-12 hours.
Terminal elimination half-life is approximately 8.3 hours (range 6–10 hours) in healthy adults, prolonged to 20–25 hours in patients with renal impairment (CrCl < 40 mL/min). No significant difference in elderly vs. young adults with normal renal function.
Primarily renal excretion of metabolites; less than 1% excreted unchanged. Biliary/fecal elimination accounts for approximately 25-30%.
Renal excretion of unchanged drug accounts for approximately 70% of elimination; approximately 10% is excreted in feces via biliary route. Total renal excretion includes both parent drug and metabolites, with cetirizine largely unchanged.
Category A/B
Category C
Antihistamine / Antiemetic
Antihistamine